Liquidia (NASDAQ:LQDA) Issues Earnings Results

Liquidia (NASDAQ:LQDA - Get Free Report) issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.03), Zacks reports. The business had revenue of $3.12 million for the quarter, compared to analysts' expectations of $3.23 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%.

Liquidia Stock Performance

Shares of NASDAQ:LQDA traded up $0.65 during trading on Thursday, reaching $19.30. The company had a trading volume of 1,833,968 shares, compared to its average volume of 1,020,154. Liquidia has a twelve month low of $8.26 and a twelve month high of $19.41. The firm has a market capitalization of $1.65 billion, a PE ratio of -11.84 and a beta of 0.24. The firm's fifty day moving average is $14.46 and its 200 day moving average is $13.32.

Insider Buying and Selling

In other news, General Counsel Russell Schundler sold 5,964 shares of the company's stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $80,931.48. Following the completion of the sale, the general counsel now owns 570,301 shares in the company, valued at approximately $7,738,984.57. This represents a 1.03% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Rajeev Saggar sold 2,450 shares of the stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $13.67, for a total value of $33,491.50. Following the transaction, the insider now owns 263,152 shares in the company, valued at approximately $3,597,287.84. This trade represents a 0.92% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 33,138 shares of company stock valued at $450,233 over the last three months. Company insiders own 30.10% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on LQDA shares. Raymond James lifted their price target on shares of Liquidia from $27.00 to $29.00 and gave the stock a "strong-buy" rating in a research note on Friday, May 9th. Needham & Company LLC restated a "buy" rating and set a $25.00 price objective on shares of Liquidia in a research report on Monday. HC Wainwright reissued a "buy" rating and issued a $29.00 price target on shares of Liquidia in a report on Monday. Finally, Scotiabank restated an "outperform" rating on shares of Liquidia in a research report on Monday, May 5th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $27.13.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).